Literature DB >> 31195146

Hepatocyte peroxisome proliferator-activated receptor α regulates bile acid synthesis and transport.

Cen Xie1, Shogo Takahashi2, Chad N Brocker3, Shijun He4, Li Chen5, Guomin Xie6, Katrina Jang7, Xiaoxia Gao8, Kristopher W Krausz9, Aijuan Qu10, Moshe Levi11, Frank J Gonzalez12.   

Abstract

Peroxisome proliferator-activated receptor alpha (PPARα) controls lipid homeostasis through regulation of lipid transport and catabolism. PPARα activators are clinically used for hyperlipidemia treatment. The role of PPARα in bile acid (BA) homeostasis is beginning to emerge. Herein, Ppara-null and hepatocyte-specific Ppara-null (Ppara∆Hep) as well as the respective wild-type mice were treated with the potent PPARα agonist Wy-14,643 (Wy) and global metabolomics performed to clarify the role of hepatocyte PPARα in the regulation of BA homeostasis. Levels of all serum BAs were markedly elevated in Wy-treated wild-type mice but not in Ppara-null and Ppara∆Hep mice. Gene expression analysis showed that PPARα activation (1) down-regulated the expression of sodium-taurocholate acid transporting polypeptide and organic ion transporting polypeptide 1 and 4, responsible for the uptake of BAs into the liver; (2) decreased the expression of bile salt export pump transporting BA from hepatocytes into the bile canaliculus; (3) upregulated the expression of multidrug resistance-associated protein 3 and 4 transporting BA from hepatocytes into the portal vein. Moreover, there was a notable increase in the compositions of serum, hepatic and biliary cholic acid and taurocholic acid following Wy treatment, which correlated with the upregulated expression of the Cyp8b1 gene encoding sterol 12α-hydroxylase. The effects of Wy were identical between the Ppara∆Hep and Ppara-null mice. Hepatocyte PPARα controlled BA synthesis and transport not only via direct transcriptional regulation but also via crosstalk with hepatic farnesoid X receptor signaling. These findings underscore a key role for hepatocyte PPARα in the control of BA homeostasis. Published by Elsevier B.V.

Entities:  

Keywords:  Bile acid homeostasis; Farnesoid X receptor; Metabolomics; Peroxisome proliferator-activated receptor α; Wy-14,643

Mesh:

Substances:

Year:  2019        PMID: 31195146      PMCID: PMC7423166          DOI: 10.1016/j.bbalip.2019.05.014

Source DB:  PubMed          Journal:  Biochim Biophys Acta Mol Cell Biol Lipids        ISSN: 1388-1981            Impact factor:   4.698


  60 in total

1.  Hepatocyte-specific PPARA expression exclusively promotes agonist-induced cell proliferation without influence from nonparenchymal cells.

Authors:  Chad N Brocker; Jiang Yue; Donghwan Kim; Aijuan Qu; Jessica A Bonzo; Frank J Gonzalez
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2017-01-12       Impact factor: 4.052

2.  Expression of ABCG5 and ABCG8 is required for regulation of biliary cholesterol secretion.

Authors:  Liqing Yu; Sarita Gupta; Fang Xu; Amy D B Liverman; Antonio Moschetta; David J Mangelsdorf; Joyce J Repa; Helen H Hobbs; Jonathan C Cohen
Journal:  J Biol Chem       Date:  2004-12-16       Impact factor: 5.157

3.  ADD1/SREBP1 activates PPARgamma through the production of endogenous ligand.

Authors:  J B Kim; H M Wright; M Wright; B M Spiegelman
Journal:  Proc Natl Acad Sci U S A       Date:  1998-04-14       Impact factor: 11.205

Review 4.  FXR signaling in the enterohepatic system.

Authors:  Tsutomu Matsubara; Fei Li; Frank J Gonzalez
Journal:  Mol Cell Endocrinol       Date:  2012-05-17       Impact factor: 4.102

Review 5.  Nutrient-sensing nuclear receptors PPARα and FXR control liver energy balance.

Authors:  Geoffrey A Preidis; Kang Ho Kim; David D Moore
Journal:  J Clin Invest       Date:  2017-03-13       Impact factor: 14.808

6.  Gemfibrozil disrupts lysophosphatidylcholine and bile acid homeostasis via PPARα and its relevance to hepatotoxicity.

Authors:  Aiming Liu; Kristopher W Krausz; Zhong-Ze Fang; Chad Brocker; Aijuan Qu; Frank J Gonzalez
Journal:  Arch Toxicol       Date:  2014-01-03       Impact factor: 5.153

7.  Bile acids induce the expression of the human peroxisome proliferator-activated receptor alpha gene via activation of the farnesoid X receptor.

Authors:  Inés Pineda Torra; Thierry Claudel; Caroline Duval; Vladimir Kosykh; Jean-Charles Fruchart; Bart Staels
Journal:  Mol Endocrinol       Date:  2003-02

8.  Farnesoid X receptor regulates bile acid-amino acid conjugation.

Authors:  Parinaz C Pircher; Jennifer L Kitto; Mary L Petrowski; Rajendra K Tangirala; Eric D Bischoff; Ira G Schulman; Stefan K Westin
Journal:  J Biol Chem       Date:  2003-05-16       Impact factor: 5.157

Review 9.  Bile-acid-induced cell injury and protection.

Authors:  Maria-J Perez; Oscar Briz
Journal:  World J Gastroenterol       Date:  2009-04-14       Impact factor: 5.742

Review 10.  Recent advances in understanding liver fibrosis: bridging basic science and individualized treatment concepts.

Authors:  Ralf Weiskirchen; Sabine Weiskirchen; Frank Tacke
Journal:  F1000Res       Date:  2018-06-27
View more
  10 in total

1.  YAP-dependent metabolic remodeling in local lymph node boosts the function of cancer cells.

Authors:  Toshihide Kashihara; Daniela Zablocki; Junichi Sadoshima
Journal:  Biotarget       Date:  2019-08-23

2.  Intestinal farnesoid X receptor signaling controls hepatic fatty acid oxidation.

Authors:  Dasheng Lu; Yameng Liu; Yuhong Luo; Jie Zhao; Chao Feng; Liming Xue; Jiale Xu; Qiong Wang; Tingting Yan; Ping Xiao; Kristopher W Krausz; Frank J Gonzalez; Cen Xie
Journal:  Biochim Biophys Acta Mol Cell Biol Lipids       Date:  2021-11-29       Impact factor: 4.698

3.  Hepatic Expression of the Na+-Taurocholate Cotransporting Polypeptide Is Independent from Genetic Variation.

Authors:  Roman Tremmel; Anne T Nies; Barbara A C van Eijck; Niklas Handin; Mathias Haag; Stefan Winter; Florian A Büttner; Charlotte Kölz; Franziska Klein; Pascale Mazzola; Ute Hofmann; Kathrin Klein; Per Hoffmann; Markus M Nöthen; Fabienne Z Gaugaz; Per Artursson; Matthias Schwab; Elke Schaeffeler
Journal:  Int J Mol Sci       Date:  2022-07-05       Impact factor: 6.208

Review 4.  Bile acid and receptors: biology and drug discovery for nonalcoholic fatty liver disease.

Authors:  Ting-Ying Jiao; Yuan-di Ma; Xiao-Zhen Guo; Yun-Fei Ye; Cen Xie
Journal:  Acta Pharmacol Sin       Date:  2022-02-25       Impact factor: 7.169

Review 5.  Obesity and Gallstones.

Authors:  Nela Melissa Parra-Landazury; Jacqueline Cordova-Gallardo; Nahum Méndez-Sánchez
Journal:  Visc Med       Date:  2021-04-23

6.  The Mechanism of Dendrobium officinale as a Treatment for Hyperlipidemia Based on Network Pharmacology and Experimental Validation.

Authors:  Lin-Zi Li; Hui-Ying Wang; Jia-Hui Huang; Kun Liu; Xiao-Jie Feng; Xi-Ming Wang; Li-Jie Zhu; Xing-Lishang He; Xiang Zheng; Hai-Long Li; Ying-Jie Dong; Bo Li; Han-Song Wu; Ning-Hua Jiang; Gui-Yuan Lv; Su-Hong Chen
Journal:  Evid Based Complement Alternat Med       Date:  2022-04-13       Impact factor: 2.650

7.  FXR-Deoxycholic Acid-TNF-α Axis Modulates Acetaminophen-Induced Hepatotoxicity.

Authors:  Tingting Yan; Nana Yan; Hong Wang; Tomoki Yagai; Yuhong Luo; Shogo Takahashi; Min Zhao; Kristopher W Krausz; Guangji Wang; Haiping Hao; Frank J Gonzalez
Journal:  Toxicol Sci       Date:  2021-05-27       Impact factor: 4.849

8.  Da-Chai-Hu-Tang Protects From Acute Intrahepatic Cholestasis by Inhibiting Hepatic Inflammation and Bile Accumulation via Activation of PPARα.

Authors:  Shihao Xu; Xi Qiao; Peike Peng; Ziyi Zhu; Yaoting Li; Mengyuan Yu; Long Chen; Yin Cai; Jin Xu; Xinwei Shi; Christopher G Proud; Jianling Xie; Kaikai Shen
Journal:  Front Pharmacol       Date:  2022-03-15       Impact factor: 5.810

Review 9.  PPARα: A potential therapeutic target of cholestasis.

Authors:  Xiaoyin Ye; Tong Zhang; Han Han
Journal:  Front Pharmacol       Date:  2022-07-18       Impact factor: 5.988

10.  The Effect of Simvastatin on Gut Microbiota and Lipid Metabolism in Hyperlipidemic Rats Induced by a High-Fat Diet.

Authors:  Qing Zhang; Xiaoyun Fan; Rui Ye; Yuzhong Hu; Tingting Zheng; Rui Shi; Wenjian Cheng; Xucong Lv; Lijiao Chen; Peng Liang
Journal:  Front Pharmacol       Date:  2020-04-29       Impact factor: 5.810

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.